These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 10202280

  • 1. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M.
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [Abstract] [Full Text] [Related]

  • 2. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.
    Pathol Res Pract; 1997 Apr; 193(11-12):767-75. PubMed ID: 9521509
    [Abstract] [Full Text] [Related]

  • 3. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I, Scher HI, Zhang ZF, Pellicer I, Hamza R, Eissa S, Khaled H, Cordon-Cardo C.
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P, Bai M, Stefanaki K, Poussias G, Rontogianni D, Zioga E, Gorgoulis V, Agnantis NJ.
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 9. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E.
    Br J Cancer; 1997 May; 75(9):1269-78. PubMed ID: 9155045
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
    Shiina H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T.
    Oncology; 1996 May; 53(3):233-40. PubMed ID: 8643227
    [Abstract] [Full Text] [Related]

  • 11. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
    Hashimoto H, Sue Y, Saga Y, Tokumitsu M, Yachiku S.
    Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Dec; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 13. [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].
    Rodríguez Alonso A, Pita Fernández S, González-Carreró J, Nogueira March JL.
    Actas Urol Esp; 2003 Feb; 27(2):132-41. PubMed ID: 12731328
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T, Minei S, Gao JP, Wang C, Satoh T, Baba S.
    Oncol Rep; 2002 Feb; 9(2):253-9. PubMed ID: 11836589
    [Abstract] [Full Text] [Related]

  • 15. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK.
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [Abstract] [Full Text] [Related]

  • 16. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease.
    Smolewski P, Niewiadomska H, Los E, Robak T.
    Int J Oncol; 2000 Sep; 17(3):603-9. PubMed ID: 10938405
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
    Kindblom LG, Ahldén M, Meis-Kindblom JM, Stenman G.
    Virchows Arch; 1995 Sep; 427(1):19-26. PubMed ID: 7551341
    [Abstract] [Full Text] [Related]

  • 18. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH.
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [Abstract] [Full Text] [Related]

  • 19. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
    Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kirkali Z.
    Pathol Res Pract; 2003 May; 199(5):323-8. PubMed ID: 12908522
    [Abstract] [Full Text] [Related]

  • 20. p53 and MDM2 in the development and progression of bladder cancer.
    Schmitz-Dräger BJ, Kushima M, Goebell P, Jax TW, Gerharz CD, Bültel H, Schulz WA, Ebert T, Ackermann R.
    Eur Urol; 1997 May; 32(4):487-93. PubMed ID: 9412812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.